Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Repla... (approximately two months after imp...)

Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)

Date:5/19/2008

approximately two months after

implantation

-- The regenerated bladder wall showed near native pharmacological and

electrophysiological functional responses by six months after

implantation

Tengion is currently conducting a GLP study of its Neo-Bladder Replacement to support a planned request to the FDA in the near future to initiate human clinical trials in 2009. Additionally, Tengion is currently conducting three Phase 2 clinical trials of its Neo-Bladder Augment at 12 leading academic medical centers across the United States: one in children with neurogenic bladder due to spina bifida, one in adults with neurogenic bladder due to spinal cord injury and one in adult patients with overactive bladder (OAB) and urge incontinence.

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo- tissues that are designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.

SOURCE Tengion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference

Post Your Comments:

(Date:11/24/2008)...s innovation leadership and long-term commitment t...Nov. 24 Schering-Plough ...al update on boceprevir, its lead investigational ...hase III development. The company believes bocepr...best-in-class protease inhibitor for treating chro...

(Date:11/24/2008)...v. 24 Schering-Plough Co...denant, its novel and selective adenosine2a recept... II dose-finding trial in patients suffering from ...g motor fluctuations and abnormal involuntary move...nted today at the company,s 2008 R&D Update me...

(Date:11/24/2008)...Nov. 24 GeneThera, Inc.,...gin offering its Real Time,PCR test for Johne,s d..., GeneThera is set to begin offering its Jo...of 2009. According to GeneThera Chairman, Dr. Ton... real time PCR test for Johne,s disease,called H...

(Date:11/24/2008).... 24 Medarex, Inc. (Nas...hase 1b clinical trial for MDX-1106 (ONO-4538: dev...fully human anti-PD-1 antibody for the treatment o... pathway may play an important role in tumor evasi...lso promote the persistence of certain chronic vir...

[0] Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C [0] Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease [1] GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009.[0] Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer

... HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGeni...n, Chief Scientific Officer will,present an update...using the Company,s proprietary synDNA(TM) technol... in Malaga, Spain between May 23,and May 25., Dr. ...ts of,synDNA(TM) based vaccines in mice, rabbits a...

... EVANSTON, Ill.--(BUSINESS WIRE)--May 23, 2007 - N...ed today results of its,pivotal Phase III trauma t...oxygen-carrying red blood cell substitute. The,tri...he treatment,of life-threatening red blood cell lo...s are not available, not for use,interchangeably w...

Other Medicine Technology:CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain 2 Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 2 Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 3 Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 4 Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 5 Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 6 Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 7 Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 8

CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study

(Date:12/1/2008)...alysis of the National Cancer Institute,s cancer r...r women experience delayed or incomplete radiation...d that this suboptimal care can lead to worse outc... Medical College and colleagues found that among a...breast cancer registry patients aged 65 and older,...

(Date:12/1/2008)...D, Mass., Dec. 1 MassMutual Retire...ts to support its increasing nonprofit business. N...mpared to last year. , , Dan Darby joined ...alist for the Western region. He reports to M. Pal... market, for MassMutual,s Retirement Services Divi...

(Date:12/1/2008)...f., Dec. 1 Senetek PLC,...ny engaged in the,development of technologies tha...today that Dynamics Group AG, specialists in the f...agement and research with offices in Zurich,Bern... Company. , The Research Report, available ...

(Date:12/1/2008)...ing, steroids effective against plantar fasciitis...HealthDay News) -- Italian researchers say they,ve...nt for the painful foot condition known as plantar...ing" and steroid injections guided by ultrasound, ...ercent success rate in tackling a condition that a...

Breaking Medicine News(10 mins):Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2 Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2 Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3 Health News:New Twist on Treatment of Foot Pain 2 Health News:New Twist on Treatment of Foot Pain 3

[0] Delays in radiation therapy lead to increased breast cancer recurrence [0] MassMutual Retirement Services Adds Two to Nonprofit Sales Team [0] Dynamics Group AG Publishes Research Report on Senetek [0] New Twist on Treatment of Foot Pain

...man holds the hand of a little boy, looking at a r...e area, which was in wreck two years ago, washed a...am village is exuding life now. Along the innocent...h of Chennai, India, new casurina saplings are kne...

...round the corner and this is the time to make new ...7 ?// Health watchers suggest- give yourself ...and food intake the whole year-round. Limiting...very important step, if you want to keep your hear...

...t Mayo Clinic have successfully isolated nanoparti...d have isolated proteins, RNA and DNA that appear ..., which appear in the December issue of the Journa...ficant because it is one step closer in solving th...

...Research Service (ARS) scientists have reported th...s of wheat have been found to produce flour with 2...ard J. Souza, research leader of the ARS Soft Whea...io and colleagues Mary J. Guitteri and Karen M. Pe...

Other Medicine News:Health News:Tsunami-Hit Coastal Regions Needs More Relief 2 Health News:Gift Yourself A Healthy Heart 2 Health News:Link Between Nanoparticles and Kidney Stones 2 Health News:Link Between Nanoparticles and Kidney Stones 3

Tsunami-Hit Coastal Regions Needs More Relief Gift Yourself A Healthy Heart Link Between Nanoparticles and Kidney Stones Improved Wheats Could Reduce Magnesium Deficiencies: Research

Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL.

Kinetic and endpoint methods for the quantitative determination of creatinine in serum.

For the quantitative determination of creatinine in serum. Fixed Time Reaction measured at 540 nm. Linearity: 25 mg/dl. Express Kit with Ready-to-Use Liquid.

For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C.

Medicine Products:

Creatinine Test Kit (enzymatic)Creatinine Reagent Set Creatinine Creatine Kinase (CK)

Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Repla...(approximately two months after imp...),Health